The unique advantages of Shuguang Holy Land's Ginkgo Leaf Droplets spark lively discussions among experts and scholars.

At the meeting, Ye Xingfu, Deputy Director of the Taizhou Municipal Administration for Market Regulation, and Shen Nuo, Deputy Secretary-General of the China Association of Traditional Chinese Medicine, delivered speeches. Academician Wang Guangji, Chairman of the Alliance, was unable to attend in person due to health reasons but still extended his congratulations via remote video on the successful convening of the Alliance’s annual conference. He also gave a significant address on the Alliance’s work, stating: "The establishment of the Ginkgo Leaf Droplet Pill Medical-Research-Enterprise Collaborative Innovation Alliance perfectly aligns with the nation’s growing emphasis on innovative development in traditional Chinese medicine. Our goal is to integrate top-tier scientific research capabilities—both domestically and internationally—to conduct comprehensive, end-to-end research spanning from herbal extracts all the way through to the final dosage form of droplet pills. Together, we aim to deliver a new generation of high-quality ginkgo leaf products to China and the world—products backed by robust evidence-based data, featuring全程 quality control, consistently reliable efficacy, and enhanced safety when used in combination with other medications." Furthermore, he expressed his hope that the Alliance will continue to evolve into a leading model for industry-academia-research collaboration within the Chinese medicinal sector, ultimately driving the sustained growth and advancement of China’s traditional Chinese medicine industry.

— Warmest congratulations on the 2018 Ginkgo Leaf Droplet Pill Medical-Research-Enterprise Collaborative Innovation Alliance Annual Conference

The 2nd Wanbang Xinnuo Kang Ginkgo Leaf Product Research and Development Summit Forum Successfully Held

On June 30, the 2018 Ginkgo Leaf Droplet Pill Medical-Research-Industry Collaborative Innovation Alliance Annual Meeting and the 2nd Wanbang Xinnaokang Ginkgo Leaf Product Research & Development Summit Forum were held in Wenling, jointly hosted by the School of Pharmacy at China Pharmaceutical University, the School of Pharmacy at Zhejiang University, and Wanbangde Pharmaceutical Group. More than 50 alliance experts from institutions including China Pharmaceutical University, Zhejiang University, Peking University, the University of Sydney, the China Academy of Chinese Medical Sciences, Beijing University of Chinese Medicine, Beijing Anzhen Hospital, West China Hospital of Sichuan University, Beijing Xiyuan Hospital, and the First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine gathered to review the significant pharmaceutical research achievements made over the past year with Wanbang Xinnaokang’s Ginkgo Leaf Droplet Pills, while also offering valuable insights and contributing their expertise to guide the future development of ginkgo leaf-based products.

At the meeting, Ye Xingfu, Deputy Director of the Taizhou Municipal Administration for Market Regulation, and Shen Nuo, Deputy Secretary-General of the China Association of Traditional Chinese Medicine, delivered speeches. Academician Wang Guangji, Chairman of the Alliance, was unable to attend in person due to health reasons but still extended his congratulations via remote video on the successful convening of the Alliance’s annual conference. He also delivered a significant speech on the Alliance’s work, stating: "The establishment of the Ginkgo Leaf Droplet Pill Medical-Research-Enterprise Collaborative Innovation Alliance aligns perfectly with the nation’s growing emphasis on innovative development in traditional Chinese medicine. Our goal is to integrate top-tier scientific research capabilities—both domestically and internationally—to conduct comprehensive, end-to-end research spanning from herbal extracts all the way through to the final dosage form of droplet pills. Together, we aim to deliver a new generation of high-quality ginkgo leaf products to China and the world—products backed by robust evidence-based data, featuring全程 quality control, consistently reliable efficacy, and enhanced safety when used in combination with other medications." Furthermore, he expressed his hope that the Alliance will continue to evolve into a leading model for industry-academia-research collaboration within the Chinese medicinal sector, ultimately driving the sustained growth and advancement of China’s traditional Chinese medicine industry.

Zhao Shouming, Chairman of Wanbangde Group, expressed his heartfelt gratitude to the experts and scholars attending the forum. He noted that the nation is currently providing strong support for scientific research and technological development in Traditional Chinese Medicine. To seize these opportunities and drive innovative growth, the alliance has already achieved significant scientific breakthroughs in the past year. Moving forward, Wanbangde Pharmaceutical Group will continue to ramp up its investment in research, further exploring the numerous valuable applications of Ginkgo biloba leaves. At the same time, the company will enhance the quality standards of traditional Chinese medicines, creating a new generation of premium products and accelerating the internationalization of Ginkgo biloba droplet pills.

At the meeting, Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director Ye Xingfu from the Taizhou Municipal Administration for Market Regulation, and Peking University Professor Tu Pengfei also presented appointment letters to the newly added experts of the alliance.

Following this, experts from the alliance delivered thematic presentations on Ginkgo Biloba Dropping Pills, covering four key areas: ingredient research, quality control, pharmacological mechanisms, and clinical evidence-based medicine. Topics included "Smart Manufacturing Practices and Exploration of Ginkgo Biloba Dropping Pills," "In Vivo and In Vitro Metabolism Studies and Mechanism of Pharmacological Effects of Ginkgo Biloba Dropping Pills," "Research Plan on Ginkgo Biloba Dropping Pills for Optic Nerve Disorders," "Ginkgo Biloba Dropping Pills in Dual-Heart Medicine—A Discussion Focused on Heart Failure Comorbid Depression," and "Progress in Clinical Pathway Interpretation and Recommendations for Ginkgo Biloba Dropping Pills in Cerebrovascular Diseases such as Cerebral Infarction." The attending experts engaged in an in-depth discussion on the significant role Ginkgo Biloba Dropping Pills play in treating cardiovascular and cerebrovascular conditions like coronary heart disease combined with diabetes, chronic heart failure, and cerebral infarction, as well as in neurodegenerative diseases affecting the optic nerve and dual-heart medicine—a burgeoning area of medical practice. They reached a consensus on the potential of these innovative applications.

The Ginkgo Leaf Droplet Pills are a nationally exclusive patented product, recognized for their unique advantages and included in the "Clinical Pathway Interpretation" compiled by the Ministry of Health. They are also the only recommended oral ginkgo leaf product for multiple conditions—including cerebral infarction, transient ischemic attack, stable coronary artery disease, and chronic stable angina treated with interventional procedures—making them the sole ginkgo-based product endorsed in the "Chinese Expert Consensus on Diagnosis and Treatment of Cardiovascular Diseases Combined with Insomnia." Additionally, these pills are the flagship demonstration research product of both the National Development and Reform Commission’s National Engineering Laboratory (the only one focused on clinical applications) and the National Key Laboratory of the Ministry of Education (specializing in active components and pharmacological effects of natural medicines). Moreover, they represent the first domestically developed pharmaceutical product to emerge from the collaborative innovation alliance among medical institutions, research institutes, and enterprises—the Ginkgo Leaf Droplet Pills Medical-Research-Industry Innovation Alliance, serving as its demonstrative research model.

Academician Wang Guangji, Chairman of the Alliance, delivers a speech via remote video.

Chairman Zhao Shouming delivers a speech

Professor Meiyan Liu from Beijing Anzhen Hospital delivered a report titled "Today's Dual-Action Ginkgo Biloba Droplets and Dual-Heart Medicine: Exploring Heart Failure Combined with Depression."

Professor Zeng Xiantao from Wuhan University delivered a report titled "Analysis of Recommended Usage for Clinical Pathways Related to Ginkgo Leaf Droplet Pills Across Indicated Conditions."

Report: "New Applications of Ginkgo Biloba Droplets in Vision-Threatening Eye Diseases"

Dr. Hong Wang, a PhD from Zhejiang University of Pharmaceutical Sciences, presented a report titled "Hypotheses on the In Vivo Metabolism and Pharmacological Mechanisms of Ginkgo Biloba Droplets."

Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director Ye Xingfu from the Taizhou Municipal Administration for Market Regulation, and Peking University Professor Tu Pengfei presented appointment letters to the newly added experts of the alliance.

Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director Ye Xingfu from the Taizhou Municipal Administration for Market Regulation, and Peking University Professor Tu Pengfei presented appointment letters to the newly added experts of the alliance.

Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director Ye Xingfu from the Taizhou Municipal Administration for Market Regulation, and Peking University Professor Tu Pengfei presented appointment letters to the newly added experts of the alliance.

Chairman Zhao Shouming, Vice Chairman Zhuang Hui, Deputy Director Ye Xingfu from the Taizhou Municipal Administration for Market Regulation, and Peking University Professor Tu Pengfei presented appointment letters to the newly added experts of the alliance.